News

Phage cocktail, AP-PA02, safely lowers P. aeruginosa load in CF trial

AP-PA02, an experimental phage therapy for people with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa respiratory infections, was well tolerated and reduced the bacterial load in the lungs, according to top-line results from a Phase 1b/2a trial. High doses of AP-PA02 were associated with durable reductions in bacterial load in the SWARM-Pa study. Pharmacokinetics data,…

Environment plays big role in lung function decline in CF children

Exposure to traffic-related air pollution is an important predictor of early lung function decline in children and adolescents with cystic fibrosis (CF), a study has found. Community deprivation — reflecting poverty, housing, income, education, and health insurance coverage — was also a significant predictor of this decline in young…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.